Skip to main content
. Author manuscript; available in PMC: 2015 Oct 14.
Published in final edited form as: Pediatr Blood Cancer. 2012 Dec 19;60(6):964–971. doi: 10.1002/pbc.24432

TABLE II.

Outcomes by Cytogenetic Risk Groups in CCG-2961 and COG AAML03P1

De novo patients OS LR EFS LR DFS LR OS IR EFS IR DFS IR
CCG-2961 post-susp [9] 72 ± 12% (n = 60) 60 ± 13% (n = 60) 62 ± 14% (n = 47) 51 ± 7% (n = 190) 39 ± 7% (n = 190) 48 ± 9% (n = 125)
COG AAML03P1 [3] 83 ± 9% (n = 78) 67 ± 11% (n = 78) 66 ± 11% (n = 70) 62 ± 7% (n = 225) 49 ± 7% (n = 225) 57 ± 8% (n = 171)